Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Business segments
Q3 2025 · $50.1MThe company’s own SEC segment disclosure.
- Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab$50.0M100%
- Transaction Service$100.0K0%
AnaptysBio, Inc. (ANAB) reported revenue of $26M in Q1 2026 (quarter ended March 31, 2026), down 8.0% from the same quarter a year earlier. That came with net loss of $53M. For the full year FY2025, revenue was $235M (+157% year on year) and net income −$13M. Its largest product in 2025-Q3 was Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab at $50M, 100% of the disclosed total, just ahead of Transaction Service at 0.2%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #102 of 145 by Smart Score